NIPD (Non Invasive Prenatal Diagnosis)
As invasive test procedures such as amniocentesis (AC) and chorionic villus sampling (CVS) have a miscarriage risk of 1%, these procedures are being replaced by Non Invasive Prenatal Testing (NIPT) on fetal DNA from maternal blood to exclude fetal aneuploidies.
Until recently NIPT was only possible for the detection of Down syndrome and some other common chromosomal anomalies (trisomy 18, trisomy 13) in the fetus.
GENDIA now offers Non-Invasive Prenatal Diagnosis (NIPD) for a limited number of monogenic disorders.
The essentials of the NIPD test are summarized below, and more details can be found in the different brochures by clicking on the respective links listed below.
- Cystic fibrosis due to specific CFTR mutations
- Achondroplasia and thanatophoric dysplasia due to specific FGFR3 mutations
- Craniosynostosis due to specific FGFR2 mutations
- Apert syndrome
- Crouzon syndrome with acanthosis nigricans
- Sex determination in case of X-linked disorders (Duchenne muscular dystrophy, hemophilia)
NIPD for monogenic disorders is currently no routine diagnostic procedure and requires individual set up:
- For dominant disorders (eg achondroplasia) NIPD can currently only exclude:
- specific paternal mutations in case the father is affected
- “de novo” (new) mutations in case none of the parents is affected but the fetus is suspected to have the disorder on ultrasound.
- For recessive disorders (bv Cystic fibrosis) NIPD can currently only exclude specific paternal mutations whereas the maternal mutation cannot be excluded. In case NIPD finds the paternal mutation to be present in the maternal blood and fetus, an invasive test procedures such as amniocentesis (AC) and chorionic villus sampling (CVS) has to be performed to determine whether also the maternal mutation is present in the fetus. Currently NIPD is only possible for a limited number of monogenic disorders, but it is expected that in the near future NIPD will become possible for many monogenic disorders.
The samples have to be sent by Express mail to GENDIA’s lab in Antwerp (Belgium), and arrive there within 2 days of withdrawal.